ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Humanis Saglık Anonim Sirketi clinical trials

Also known as Pharmactive.

Part of Saya Holding.

What moves in its pipeline, every Monday. Free with an account during the beta.

The registry lists 42 studies whose lead sponsor is Humanis Saglık Anonim Sirketi. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Humanis Saglık Anonim Sirketi with JW Pharmaceutical and Jiangsu HengRui Medicine →

Pipeline: 18 programs

Each counted once: 18 with a study Humanis Saglık Anonim Sirketi leads registered in the last two years.

  • Phase 1

5 from the earlier phases, besides the phase-3 view.

Program
Trijardy® XR TabletsPhase 1 · 0 live · Diabetes Mellitus, Type 2☆ Track
bempedoic acidPhase 1 · 0 live · Hypercholesterolemia☆ Track
Empagliflozin/LinagliptinPhase 1 · 0 live · Diabetes Mellitus, Type 2☆ Track
selexipagPhase 1 · 0 live · Pulmonary Arterial Hypertension☆ Track
Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)Phase 1 · 0 live · Diabetes Mellitus, Type 2☆ Track

13 more — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

Not counted: 3 approved drugs Humanis Saglık Anonim Sirketi gives alongside its own in its studies — empagliflozin (with Trijardy® XR Tablets); linagliptin (with Trijardy® XR Tablets); metformin (with Trijardy® XR Tablets). Our rule: a drug many companies test, in every study Humanis Saglık Anonim Sirketi led of it in the last two years beside a drug of its own.

“Registry” is the highest phase of Humanis Saglık Anonim Sirketi’s own registered studies; Humanis Saglık Anonim Sirketi’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Humanis Saglık Anonim Sirketi’s studies test, most studies first; none is open now — 29 drugs with a page of their own. Each count opens the studies in search.

Studies, none open

Show 19 more

All 42 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Completed42100%

Phase

  • Phase 140
  • Phase 22
  • Phase 31

Where

Over the years

  1. 19
  2. 20
  3. 21
  4. 22
  5. 23
  6. 1224
  7. 25
  8. 626

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Humanis Saglık Anonim Sirketi.

  • Humanis Saglık Anonim Sirketi
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    42 studies

Focus areas

Conditions Humanis Saglık Anonim Sirketi leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 42 of 42.